We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Dr. Lewis Cantley's episode on Peter Attia, M.D. blog: Episode #110 – Cancer metabolism, cancer therapies, and the discovery of PI3K

Monday, May 11, 2020

#110 – Lew Cantley, Ph.D.: Cancer metabolism, cancer therapies, and the discovery of PI3K
"If I get a result that suddenly doesn't make sense, to me that's more exciting. . .if you figure out why it didn't work and what was wrong, then that's where most breakthroughs come from." — Lew Cantley

Please click here to access the full episode.

In this episode, Lew Cantley, Professor of Cancer Biology and Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College in NYC, walks us through his amazing discovery of phosphoinositide 3-kinase (PI3K) and the implications for the care of patients with cancer. He explains various combinations of therapies being tested and used, including the possibility of pairing prescriptive nutritional therapies to increase the efficacy of drugs like PI3K inhibitors. Lew also explains the metabolic nature of cancer through the lens of his research into the connection between sugar consumption, insulin resistance, and tumor growth. Additionally, Lew provides some details about his exciting new clinical trial that is just now enrolling patients with stage 4 breast cancer and endometrial cancer.

This story first appeared on the Peter Attia, M.D. blog.